Biotechnology

The Oxford Science Park is expanding in the United Kingdom to provide sophisticated environments for research and discovery. Three new buildings will rise in the innovation district, which is majority owned by Oxford University's Magdalen College. Designed by Scott Brownrigg, The Daubeny Project will offer a total of 450,000 sf of leading-edge life science space supported by enhanced lab infrastructure. Dramatic colonnades on the ground floor will open onto light-filled areas for reception, interaction, and collaboration.

BeiGene opened an $800 million center for biologics manufacturing and research in July of 2024 in Hopewell, N.J. Sited on 42 acres at the Princeton West Innovation Campus, the development provides 400,000 sf of dedicated space for commercial-stage production of cancer therapies. A 100,000-sf lab building accommodates clinical R&D suites and collaborative office settings. As BeiGene's U.S. headquarters and flagship manufacturing facility, the highly flexible complex integrates universal design principles to create an adaptable, human-centric environment.

BXP recently completed a 113,000-rsf innovation hub in Waltham, Mass. Designed by TRIA, 103 CityPoint aims to reshape corporate culture for science and technology tenants, energizing its workforce and accelerating growth. The flexible flour-story structure provides 80 percent laboratory and office space, with 20 percent accommodating a double-height cGMP manufacturing area spanning approximately 25,000 sf.

The Davis Companies and Invesco Real Estate completed construction in June of 2024 on a 215,000-sf research facility in Cambridge. Designed by Jacobs, 101 Smith Place is the third structure in a new life sciences cluster called The Quad and offers 161,616 rsf of Class A lab and office space. Features include:

Merck is expanding its Darmstadt headquarters campus with the construction of a $66 million quality control facility for MilliporeSigma, the company’s life science business. Spanning approximately 105,000 sf, the four-story building will provide GMP labs and cleanrooms for the testing of medicines and biological agents. The flexible structure is designed to enhance operational efficiencies and will bring 135 employees from different departments together in one collaborative location.

The $93 million Agriculture & Natural Resources Building (ANRB) at the University of Tennessee, Knoxville provides enhanced research, education, and collaboration with advanced technology, specialized labs, flexible classrooms, a large commons area, a 500-seat auditorium, lecture halls, seamless connections to nearby academic buildings, and a welcoming pedestrian plaza to engage the community. A biophilic design connects students, faculty, and staff with nature through the use of clerestory windows and a green roof that acts as an exterior living room with research gardens.  

WACKER opened the mRNA Competence Center in June of 2024 in Halle an der Saale, Germany. Representing an investment of over €100 million, the next-generation facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA). The building spans a total floor area of 79,653 sf and accommodates four new lines supported by advanced infrastructure, including 17,222 sf of glass-enclosed cleanroom space for bioprocessing under controlled conditions. 

Sanofi opened a 20,000-sf biomanufacturing center in May of 2024 in Toronto. Producing adult and pediatric vaccines for pertussis, diphtheria, and tetanus, the project significantly increases capacity to meet growing demand in Canada and around the world. The next-generation facility features advanced bioprocessing suites supported by highly efficient infrastructure. Commissioning is currently under way, with full operations slated to commence in mid-2025.

The International Society for Pharmaceutical Engineering (ISPE) has announced the 2024 Facility of the Year Awards category winners. The awards include:

The University of Delaware broke ground in April of 2024 on the Securing American Biomanufacturing Research and Education (SABRE) Center. The $150 million facility will enhance the R&D capabilities of the adjacent National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) while driving the creation of a skilled workforce. Serving as a living laboratory for the formulation of best practices, the 70,000-sf building is envisioned as a place to scale up and mature new production methods.

Delancey is planning to construct a £400 million innovation hub in London's Knowledge Quarter. Designed by Gardiner & Theobald and KPF, the 194,000-sf structure will offer 130,000 sf of leasable research space for biomedical companies, technology firms, and start-up enterprises. The highly adaptable facility will feature next-generation laboratories, traditional and open offices, a maker space, and a community event venue. Typical floors will have access to an amenity terrace with a range of interactive settings.

FUJIFILM Diosynth Biotechnologies is constructing a $3.2 billion pharmaceutical campus in Holly Springs, N.C. Integrating sophisticated automation technologies, the multi-building development will enable large-scale cell culture manufacturing for the creation of bulk drug substances. Ground was broken in October of 2021 on the first phase, a $2 billion production center slated for completion in early 2025. A subsequent investment of $1.2 billion will establish an additional 425,000-sf plant that will begin operations in 2028.

Novo Nordisk has executed a long-term, full-building lease for a 165,940-rsf property at the Alexandria Center for Life Science in Waltham, Mass. Located at 60 Sylvan Road, the research facility is being redeveloped to provide next-generation environments for biomedical discovery. Neighborhoods of labs, offices, and collaboration spaces will foster interaction between investigators to accelerate the discovery and commercialization of new therapies. Occupancy is expected in 2025.

Lonza is investing $1.2 billion to purchase a pharmaceutical manufacturing campus in Vacaville, Calif. Presently occupied by Genentech, a subsidiary of Roche, the 427,000-sf complex provides a total bioreactor capacity of approximately 330 liters. Lonza is offering employment to 750 personnel at the site, which will continue to supply its current products at a committed volume of 30 percent throughout 2025.

Pfizer has signed a 15-year lease for 230,000 sf of Class A research space in San Diego to accommodate its growing oncology division. The global pharmaceutical manufacturer will occupy two of the three buildings that are currently under construction at Breakthrough Properties' Torrey View campus. Leading-edge wet labs will advance the creation of novel therapies, accompanied by flexible offices and collaboration spaces.